Literature DB >> 6386489

Effects of captopril on pulmonary haemodynamics.

C Richard, J L Ricome, A Rimailho, M Conrad, P Auzépy.   

Abstract

The effects of oral captopril on pulmonary haemodynamics were studied in two groups of 6 patients, one of subjects with chronic respiratory failure (PaO2 52 +/- 5.1 mmHg, PaCO2 54 +/- 2.1 mmHg), and the others with chronic heart failure and high plasma renin activity. Two potential mechanisms of its actions were assessed, namely inhibition of hypoxic vasoconstriction and inhibition of the possible effects of angiotensin II on the pulmonary circulation. There were significant (p less than 0.05) decreases in mean arterial pressure, pulmonary wedge pressure and in systemic arterial resistance associated with improvement in cardiac index in both groups. In the chronic respiratory failure group there was no change in blood gases, mean pulmonary arterial pressure or pulmonary vascular resistance. An increase in driving pressure (p less than 0.05) indicated that captopril had had no effect on pulmonary haemodynamics. In chronic heart failure, mean pulmonary arterial pressure and pulmonary capillary wedge pressure were decreased by a similar extent, so that driving pressure and pulmonary vascular resistance were not changed. It is concluded that oral captopril did not inhibit hypoxic vasoconstriction, and that it modified pulmonary haemodynamics in chronic heart failure patients with high renin activity only as a consequence of reduction in systemic afterload.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386489

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

1.  Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat.

Authors:  R M Zakheim; L Mattioli; A Molteni; K B Mullis; J Bartley
Journal:  Lab Invest       Date:  1975-07       Impact factor: 5.662

2.  Effect of angiotensin on hypoxic pulmonary vasoconstriction in isolated dog lung.

Authors:  J M Alexander; M D Nyby; K A Jasberg
Journal:  J Appl Physiol       Date:  1976-07       Impact factor: 3.531

3.  An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.

Authors:  H Gavras; H R Brunner; J H Laragh; J E Sealey; I Gavras; R A Vukovich
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure.

Authors:  D P Faxon; M A Creager; J L Halperin; H Gavras; J D Coffman; T J Ryan
Journal:  Circulation       Date:  1980-05       Impact factor: 29.690

6.  Effects of vasodilators on pulmonary hemodynamics and gas exchange in left ventricular failure.

Authors:  G Pierpont; K A Hale; J A Franciosa; J N Cohn
Journal:  Am Heart J       Date:  1980-02       Impact factor: 4.749

7.  Inhibition of hypoxic pulmonary vasoconstriction by nifedipine.

Authors:  G Simonneau; P Escourrou; P Duroux; A Lockhart
Journal:  N Engl J Med       Date:  1981-06-25       Impact factor: 91.245

8.  Feline hypoxic pulmonary vasoconstriction is not blocked by the angiotensin I-converting enzyme inhibitor, captopril.

Authors:  R L Prewitt; C W Leffler
Journal:  J Cardiovasc Pharmacol       Date:  1981 Mar-Apr       Impact factor: 3.105

9.  Failure of saralasin acetate, a competitive inhibitor of angiotensin II, to diminish alveolar hypoxic vasoconstriction in the dog.

Authors:  C A Hales; E T Rouse; H Kazemi
Journal:  Cardiovasc Res       Date:  1977-11       Impact factor: 10.787

10.  Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease.

Authors:  A P Niarchos; H H Whitman; J E Goldstein; J H Laragh
Journal:  Am Heart J       Date:  1982-10       Impact factor: 4.749

View more
  2 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Effects of captopril in patients with chronic obstructive pulmonary disease and secondary pulmonary hypertension.

Authors:  D Patakas; D Georgopoulos; H Rodini; P Christaki
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.